1. Home
  2. JELD vs PEPG Comparison

JELD vs PEPG Comparison

Compare JELD & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$1.37

Market Cap

152.7M

ML Signal

HOLD

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$2.51

Market Cap

179.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
PEPG
Founded
1960
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.7M
179.4M
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
JELD
PEPG
Price
$1.37
$2.51
Analyst Decision
Hold
Strong Buy
Analyst Count
3
8
Target Price
$1.93
★ $10.19
AVG Volume (30 Days)
★ 1.5M
936.2K
Earning Date
11-03-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 25.61
EPS
N/A
★ N/A
Revenue
★ $3,211,181,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.28
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.93
$1.31
52 Week High
$4.90
$7.80

Technical Indicators

Market Signals
Indicator
JELD
PEPG
Relative Strength Index (RSI) 41.39 45.94
Support Level $1.36 $2.24
Resistance Level $2.25 $2.62
Average True Range (ATR) 0.14 0.23
MACD -0.01 0.03
Stochastic Oscillator 28.03 32.20

Price Performance

Historical Comparison
JELD
PEPG

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Share on Social Networks: